ormal saline versus heparin flushes in paediatric oncology: a pilot randomised controlled trial

Phase 3

Completed

• Conditions: Central venous access device complications; Children's cancer; Cancer - Children's - Leukaemia & Lymphoma; Cancer - Children's - Other

• Registration Number: ACTRN12619000393156
• Lead Sponsor: Queensland Children's Hopsital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-12
• Study Completion: 2020-09-24
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

•Ages 0 – 18years
•Have a central venous access device in situ;
•Diagnosed with an oncological or malignant haematological condition
•Informed consent to participate

Exclusion Criteria

• End of life pathway
• Pre-existing coagulopathic condition not related to current diagnosis or treatment such as (but not limited to): Haemophilia A & B or other factor deficiency; Idiopathic Thrombocytopenic Purpura (ITP); Von Willibrand’s disease
• Coagulation disorders related to current diagnosis or treatment e.g. Disseminated Intravascular Coagulopathy (DIC)
• Current treatment with PEG-Asparaginase
• Allergy to heparin
• Admission to Paediatric Intensive Care Unit (PICU)
• Admission to regional hospital or alternative healthcare facility
• Previous study participation
•BMT planned during study period/ or currently in progress
.

Study & Design

• Study Type: Interventional
• Study Design: Not specified